Diffuse large B-cell non-Hodgkin's lymphoma and osteosclerotic myeloma with features of POEMS syndrome.
Diffuse large B-cell non-Hodgkin's lymphoma and osteosclerotic myeloma with features of POEMS syndrome. Proc (Bayl Univ Med Cent). 2016 Jul;29(3):306-8 Authors: Ngamdu KS, Torabi A, Badri N, Teleb M, Gaur S Abstract Multiple myeloma is a clonal hematopoietic neoplasm characterized by the proliferation of malignant plasma cells and associated end-organ damage, most notably lytic lesions in the bones. Osteosclerotic myeloma is an unusual variant of the disease in which the skeletal involvement is characterized by sclerotic lesions instead of classical lytic lesions. The disease can be associated with paraneoplastic symptoms, which have been given the acronym POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes). In addition to clonal plasma cell dyscrasias, some cases of POEMS syndrome are associated with Castleman's disease, and in 11% to 30% of the cases both Castleman's disease and clonal plasma cell proliferation are present. POEMS syndrome has rarely been described in patients with non-Hodgkin's lymphoma. PMID: 27365880 [PubMed]
Authors: Mailhot Vega RB, Hoppe BS PMID: 31976780 [PubMed - as supplied by publisher]
Publication date: Available online 25 January 2020Source: Best Practice &Research Clinical HaematologyAuthor(s): Chutima Kunacheewa, Elisabet E. ManasanchAbstractMultiple myeloma, a bone marrow cancer, is preceded by precursor stages called monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Over the past few years, highly effective and safe therapies have been made available to treat multiple myeloma. This represents a major breakthrough and has major therapeutic implications. Treatment for multiple myeloma has evolved to include treatment of precursor stages (early treatment) as these thera...
Over the past several years, a wave of new cancer immunotherapy agents referred to as immune checkpoint inhibitors (ICIs) have transformed the standard of care for patients with cancer. ICIs are most commonly used in advanced cancers with palliative intent and recently as frontline therapy for some cancers. These new agents have been shown to extend overall survival (OS) and progression free survival (PFS) in patients with lung cancer, melanoma, Hodgkin lymphoma, renal cell carcinoma, urothelial carcinoma, Merkel cell carcinoma, head and neck cancer, and more.
Tumor necrosis factor (TNF) inhibitors are among the most effective treatments for inflammatory bowel disease, but questions about cancer risk have kept some clinicians from prescribing them.Medscape Medical News
Patients receiving multiple, concurrent intravenous (IV) infusions often face a serious riskâthe potential for misconnected tubing lines and dosing error. âNurses check lines to make sure there are no mix-ups, unintended disconnections, or wrong doses. The consequences can be severe,â explained Elmer Vera, a registered nurse working in critical care for 18 years. âAs the treatments for ailments become more advanced, the danger associated with multiple IV infusions continue to take lives right before the very eyes of the people who are responsible for t...
CONCLUSIONS: Although pSS is associated with a higher risk of developing NHL, the risk of NHL appears to have decreased compared with that in previous studies. Our study suggests that the risk of NHL or thyroid cancer with SS is not higher than that reported in previous studies. PMID: 31969226 [PubMed - as supplied by publisher]
Anti-Tumor Necrosis Factor (aTNF) agents are among the most effective medications used to treat pediatric inflammatory bowel diseases (pIBD). Despite their effectiveness, concerns regarding an association with lymphoma limit their use in everyday practice. We sought to determine the incidence rate and absolute risk of lymphoma in pIBD patients receiving aTNF treatment using a large, geographically diverse administrative insurance claims database.
CONCLUSION: Our results suggest that sarcoidosis is a new subset in the spectrum of paraneoplastic syndrome. We propose that lymphoproliferative disorders should be considered in patients with cutaneous sarcoidosis who have a poor response to conventional therapy or whose skin biopsy shows a significant number of mitoses. PMID: 29779211 [PubMed - as supplied by publisher]